|
Market Closed –
|
|
|||
|
17.44 USD |
+2.11% |
17.87 |
+2.47% | |
Published on 06/03/2025 at 16:58
© MT Newswires – 2025
|
CareDx Launches New $50 Million Share Buyback Plan |
04:58pm |
MT |
|
CareDx Announces Repurchase Of 5% Of Outstanding Shares |
04:34pm |
RE |
|
Caredx Insider Sold Shares Worth $523,413, According to a Recent SEC Filing |
Jun. 02 |
MT |
|
Caredx Insider Sold Shares Worth $465,022, According to a Recent SEC Filing |
May. 14 |
MT |
|
CareDx, Inc, Q1 2025 Earnings Call, Apr 30, 2025 |
Apr. 30 |
|
|
CareDx, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 |
Apr. 30 |
CI |
|
Earnings Flash (CDNA) CAREDX INC. Reports Q1 Adjusted EPS $0.09 |
Apr. 30 |
MT |
|
Earnings Flash (CDNA) CAREDX INC. Reports Q1 Revenue $84.7M, vs. FactSet Est of $84.4M |
Apr. 30 |
MT |
|
CareDx, Inc Reaffirms Earnings Guidance for Full Year 2025 and Provides Earnings Guidance for the Year 2027 |
Apr. 30 |
CI |
|
CareDx, Inc. Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting |
Apr. 24 |
CI |
|
CareDx, Inc Launches Two Expanded Indications for AlloSure Testing Services |
Mar. 11 |
CI |
|
CareDx, Inc, Q4 2024 Earnings Call, Feb 26, 2025 |
Feb. 26 |
|
|
Earnings Flash (CDNA) CAREDX INC. Reports Q4 Revenue $86.6M, vs. FactSet Est of $84.1M |
Feb. 26 |
MT |
|
Earnings Flash (CDNA) CAREDX INC. Reports Q4 Adjusted EPS $0.18 |
Feb. 26 |
MT |
|
CareDx, Inc announces an Equity Buyback for $50 million worth of its shares. |
Feb. 26 |
CI |
|
CareDx, Inc. Provides Revenue Guidance for the Full Year 2025 |
Feb. 26 |
CI |
|
CareDx, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 26 |
CI |
|
CareDx, Inc. Announces Study Showing Alloseq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients |
Feb. 20 |
CI |
|
CareDx, Inc authorizes a Buyback Plan. |
Jan. 31 |
CI |
|
CareDx Shares Rise Following Upgrade From Wells Fargo |
Jan. 15 |
MT |
|
Wells Fargo Upgrades CareDx to Equalweight From Underweight, Adjusts Price Target to $24 From $28 |
Jan. 15 |
MT |
|
CareDx, Inc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 04:30 PM |
Jan. 14 |
|
|
CareDx, Inc Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2024 and Provides Revenue Guidance for the Year 2025 |
Jan. 13 |
CI |
|
CareDx, TC BioPharm Collaborate to Use AlloCell Test for Achieve Trial |
Dec. 11 |
MT |
|
CareDx, Inc’s Equity Buyback announced on December 6, 2022 has expired. |
Dec. 01 |
CI |
CDNA: Dynamic Chart
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
More about the company
Buy
Average target price
29.29USD
Spread / Average Target
+71.46%
Consensus
Select your edition
All financial news and data tailored to specific country editions
